Breakthrough Bleeding
8
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
12.5%
1 terminated out of 8 trials
87.5%
+1.0% vs benchmark
50%
4 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (8)
Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant
Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users
Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™
Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale
Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®
Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?